NEW YORK--(BUSINESS WIRE)--Pfizer Inc said today that the U.S. Food and Drug Administration (FDA) approved TOVIAZ TM (fesoterodine fumarate) extended release tablets for the treatment of overactive ...
Study Shows Higher Dose Of Toviaz ® (fesoterodine fumarate) Offers Greater Efficacy In Reducing Urge Urinary Incontinence In Patients With Overactive Bladder NEW YORK--(BUSINESS WIRE)-- Pfizer Inc.
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today top-line results for Toviaz (fesoterodine fumarate) Study A0221048 - Effectiveness and Safety of a Flexible Dose Regimen for Patients ...
Patients treated with Toviaz® (fesoterodine fumarate) 8 mg extended release tablets had greater and statistically significant reductions in urge urinary incontinence episodes at week 12 (P=0.017) ...
Study Shows Higher Dose Of Toviaz ® (fesoterodine fumarate) Offers Greater Efficacy In Reducing Urge Urinary Incontinence In Patients With Overactive Bladder The safety and tolerability profile of ...
Structurally related to the most prescribed OAB medication, Pfizer ´ s Detrol ® LA (tolterodine tartrate extended release capsules), TOVIAZ can help regulate the involuntary contractions of the ...
NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) announced today top-line results for Toviaz (fesoterodine fumarate) Study A0221048 – Effectiveness and Safety of a Flexible Dose Regimen for ...
NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) announced today top-line results for Toviaz (fesoterodine fumarate) Study A0221048 – Effectiveness and Safety of a Flexible Dose Regimen for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback